Trials / Unknown
UnknownNCT05184946
Clinical Study of Camrelizumab Combined With SOX in the Adjuvant Treatment of Advanced Gastric Adenocarcinoma or Gastric Esophageal Junction Adenocarcinoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 72 (estimated)
- Sponsor
- The Second Affiliated Hospital of Shandong First Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To study the efficacy and safety of camrelizumab combined with SOX regimen for adjuvant therapy of stage III gastric cancer
Detailed description
The purpose of this study is to explore the efficacy of anti-PD1 therapy combined with SOX for adjuvant therapy of advanced gastric cancer compared to the standard SOX regimen. Besides the efficacy, we focus on the safety and quality of life in the new treatments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Camrelizumab Combined with SOX | Administer camrelizumab and SOX regimen in the adjuvant treatment of advanced gastric adenocarcinoma or gastric esophageal junction adenocarcinoma |
Timeline
- Start date
- 2021-10-09
- Primary completion
- 2025-10-08
- Completion
- 2025-10-08
- First posted
- 2022-01-11
- Last updated
- 2022-01-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05184946. Inclusion in this directory is not an endorsement.